Komori
Financial results presentation4884Kringle Pharma,Inc.Pharmaceuticals

Third-Quarter Financial Results for the Fiscal Year Ending September 2026 (Financial Results Presentation)

For the nine months ended the third quarter of the fiscal year ending September 2026, revenue increased from ¥53 million in the same period of the previous year to ¥323 million, primarily due to the supply of active pharmaceutical ingredients to クラリス and other factors, while the operating loss narrowed from ¥738 million to ¥633 million. In the acute phase of spinal cord injury, the Company began an additional Phase 3 trial, and for vocal fold scarring, it entered into a basic agreement with 丸石製薬 covering exclusive domestic sales.

Worth reading
37Immaterial
Scored from 4 of 6 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
270
¥ million (year-on-year increase in revenue)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Financial results presentationQ3 FY20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥323 million
Operating profit¥-633 million
Ordinary income¥-628 million
Net income¥-631 million
Selling, general and administrative expenses¥887 million
Full-year earnings forecast
Sales¥332 million
Selling, General and Administrative Expenses¥1,351 million
Research and development costs¥973 million
Operating loss¥-1,018 million
Ordinary loss¥-1,018 million
Income Taxes¥1 million
Quarterly net loss¥-1,020 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue: supply of active pharmaceutical ingredients to クラリス and technology access fees. Research and development expenses: preparation costs for an additional spinal cord injury trial, preparation costs for U.S. development, including an IND filing, and clinical trial costs for vocal fold scarring.
New initiatives
  • Submission of the clinical trial notification and start of an additional Phase 3 trial for acute spinal cord injury
  • Basic agreement with 丸石製薬 on exclusive domestic sales of a treatment for vocal fold scarring
  • Start of joint research on protein biomarkers with Keio University
  • Participation in the international SCI PFDD consortium
  • Preparation for U.S. development, including an IND filing
  • Development of a commercial formulation for vocal fold scarring
Key KPIsA metric the company considers important as a management benchmark.
  • Improvement rate from AIS A to AIS C or above in the Phase 3 trial for acute spinal cord injury12 %
  • Improvement rate from AIS A to AIS B or above in the Phase 3 trial for acute spinal cord injury56 %
  • Percentage of patients with reduced MRI abnormal areas in the Phase 3 HGF treatment group52 %
  • Number of enrolled cases in the Phase 3 trial for vocal fold scarring65 cases
  • Warrant exercise rate87.6 %
Financial targets
Equity ratio
Actual value60.9 %
Market Size / Share
  • Acute spinal cord injury, Japan¥120 100 million
  • Acute spinal cord injury, worldwide¥600 100 million
  • Vocal fold scarring, Japan¥50 100 million
  • Vocal fold scarring, worldwide¥300 100 million
  • ALS, Japan¥200 100 million
  • ALS, worldwide¥1,000 100 million
Number of employees
Number of Employees19 people
Reference dateEnd of June 2026
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredQ3 FY2026
Net Sales¥323 million
Operating profit¥-633 million
Ordinary income¥-628 million
Net income¥-631 million
Selling, general and administrative expenses¥887 million
Full-year earnings forecastSales ¥332 million / Cost of sales Not disclosed / Selling, General and Administrative Expenses ¥1,351 million / Research and development costs ¥973 million / Operating loss ¥-1,018 million / Ordinary loss ¥-1,018 million / Extraordinary Gains and Losses Not disclosed / Income Taxes ¥1 million / Quarterly net loss ¥-1,020 million
Breakdown of Factors Affecting the ChangeRevenue: supply of active pharmaceutical ingredients to クラリス and technology access fees. Research and development expenses: preparation costs for an additional spinal cord injury trial, preparation costs for U.S. development, including an IND filing, and clinical trial costs for vocal fold scarring.
Key KPIsIndicator name Improvement rate from AIS A to AIS C or above in the Phase 3 trial for acute spinal cord injury / Value 12 % / Year on year against the same period last year Not disclosed, Indicator name Improvement rate from AIS A to AIS B or above in the Phase 3 trial for acute spinal cord injury / Value 56 % / Year on year against the same period last year Not disclosed, Indicator name Percentage of patients with reduced MRI abnormal areas in the Phase 3 HGF treatment group / Value 52 % / Year on year against the same period last year Not disclosed, Indicator name Number of enrolled cases in the Phase 3 trial for vocal fold scarring / Value 65 cases / Year on year against the same period last year Not disclosed, Indicator name Warrant exercise rate / Value 87.6 % / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 19 people / Reference date End of June 2026
Financial targetsEquity ratio Actual value 60.9 %
Market Size / ShareSubject Acute spinal cord injury, Japan / Market Size ¥120 100 million, Subject Acute spinal cord injury, worldwide / Market Size ¥600 100 million, Subject Vocal fold scarring, Japan / Market Size ¥50 100 million, Subject Vocal fold scarring, worldwide / Market Size ¥300 100 million, Subject ALS, Japan / Market Size ¥200 100 million, Subject ALS, worldwide / Market Size ¥1,000 100 million
New initiativesSubmission of the clinical trial notification and start of an additional Phase 3 trial for acute spinal cord injury, Basic agreement with 丸石製薬 on exclusive domestic sales of a treatment for vocal fold scarring, Start of joint research on protein biomarkers with Keio University, Participation in the international SCI PFDD consortium, Preparation for U.S. development, including an IND filing, Development of a commercial formulation for vocal fold scarring
Items this document does not state (17)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The increase in revenue was attributable to the supply of active pharmaceutical ingredients to クラリス and technology access fees. The increase in research and development expenses was attributable to preparation costs for an additional spinal cord injury trial, preparation costs for U.S. development, including an IND filing, and clinical trial costs for vocal fold scarring.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Third-Quarter Financial Results for the Fiscal Year Ending September 2026 (Financial Results Presentation) | Kringle Pharma,Inc. (4884) timely disclosure | Komori